Let's stand up to COVID-19

Major scientific breakthrough to treat COVID-19

January 27, 2021

On January 22, 2021, the Montreal Heart Institute announced positive results from COLCORONA trial.

The COLCORONA study manuscript is now available in the public domain.

READ THE MANUSCRIPT

ANSWERS TO FREQUENTLY ASKED QUESTIONS

Colcorona is a home-based clinical trial that determines whether short-term treatment with an existing medication reduces the risk of mortality and lung complications related to COVID-19.

It is a randomized, placebo-controlled study. It is double-blind - which means neither doctor nor patient will know whether you are taking the trial medication or a placebo.

United States: New York City Tri-State area, San Francisco, Los Angeles, Bakersfield, Downey, Miami, Jacksonville, Houston, Dallas, Phoenix, Yuma, Rochester, Tupelo, Greenville, Chapel Hill, Little Rock 

Canada: Quebec, Ontario, British-Columbia

Spain: Madrid

South Africa: Cape Town

Brazil: San Paolo

Greece: Athens, Kozani, Alexandroupoli, Elefsina, Patras

KEY TRIAL REQUIREMENTS

You must have been diagnosed with and currently have COVID-19

You must be 40 years old or over

Trial lasts 30 days from home

Daily intake of study medication or placebo

You must not be in hospital due to COVID-19

You must not be pregnant or breastfeeding

 

SPONSORS

This clinical trial is supported by

COLCORONA

Let's stand up to COVID-19, while sitting at home 

Copyright @ 2020
All rights reserved